A Randomized, Two-Sequence, Crossover, Multi-Site Study to to assess the success rate of using the pramlintide acetate pen (Sun Pharmaceutical Industries Ltd.) compared to SymlinPen® (AstraZeneca Pharmaceuticals LP) in subjects with Type 1 and Type 2 Diabetes
The study will evaluate and compare the success rates of the use and the potential risks associated with subjects who alternate between pramlintide acetate pen injectors of 60 and 120 (Sun Pharmaceutical Industries Ltd.) and SymlinPen® of 60 and 120.
you will provide to a pad injection simulation, no will have to puncture.
